购物车
全部删除
您的购物车当前为空
别名 蟾毒灵
Bufalin 是蟾酥中的一种成分,是Na+/K+-ATPase 抑制剂,具有抗肿瘤活性,可与其基 α1、α2 和 α3 结合,Kd 值分别为 42.5、45 和 40 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Bufalin 是蟾酥中的一种成分,是Na+/K+-ATPase 抑制剂,具有抗肿瘤活性,可与其基 α1、α2 和 α3 结合,Kd 值分别为 42.5、45 和 40 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 322 | 现货 | |
| 5 mg | ¥ 772 | 现货 | |
| 10 mg | ¥ 1,320 | 现货 | |
| 25 mg | ¥ 2,230 | 现货 | |
| 50 mg | ¥ 3,350 | 现货 | |
| 100 mg | ¥ 4,160 | 现货 | |
| 200 mg | ¥ 5,930 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 848 | 现货 |
| 产品描述 | Bufalin is an active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in Y cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway. |
| 靶点活性 | Na+, K+-ATPase α3:40 nM (Kd), Na+, K+-ATPase α1:42.5 nM (Kd), Na+, K+-ATPase α2:45 nM (Kd) |
| 别名 | 蟾毒灵 |
| 分子量 | 386.52 |
| 分子式 | C24H34O4 |
| CAS No. | 465-21-4 |
| Smiles | [H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)c3ccc(=O)oc3)[C@@]1(C)CC[C@H](O)C2 |
| 密度 | 1.226 g/cm3 |
| 存储 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (258.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.35 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多